
TY  - JOUR
TI  - ABSTRACTS—POSTERS
JO  - Alcoholism: Clinical and Experimental Research
VL  - 33
IS  - s1
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2009.00957.x
DO  - doi:10.1111/j.1530-0277.2009.00957.x
SP  - 11A
EP  - 265A
PY  - 2009
ER  - 

TY  - JOUR
TI  - Melanoma 2010 Congress
JO  - Pigment Cell & Melanoma Research
VL  - 23
IS  - 6
SN  - 1755-1471
UR  - https://doi.org/10.1111/j.1755-148X.2010.00767.x
DO  - doi:10.1111/j.1755-148X.2010.00767.x
SP  - 874
EP  - 1004
PY  - 2010
ER  - 

TY  - JOUR
AU  - Zha, Xiaolong
AU  - Sun, Bolin
AU  - Zhang, Rufan
AU  - Li, Chen
AU  - Yan, Zuoqin
AU  - Chen, Jifei
TI  - Regulatory effect of microRNA-34a on osteogenesis and angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head
JO  - Journal of Orthopaedic Research
JA  - J. Orthop. Res.
VL  - 36
IS  - 1
SN  - 0736-0266
UR  - https://doi.org/10.1002/jor.23613
DO  - doi:10.1002/jor.23613
SP  - 417
EP  - 424
KW  - GIOFH
KW  - Dex
KW  - mir-34a
KW  - osteogenesis
KW  - angiogenesis
PY  - 2018
AB  - ABSTRACT Glucocorticoid-induced osteonecrosis of the femoral head (GIOFH) is a common and devastating orthopedic disease, and its underlying mechanism remains unclear. The aim of this study was to determine the role of microRNA-34a (mir-34a) in GIOFH. C57 mouse mesenchymal stem cells (mMSCs) and human umbilical vein endothelial cells (HUVECs) were cultured with dexamethasone (Dex). A total of 48 adult rats were treated with glucocorticoids, and after the onset of GIOFH, each femoral head was removed. Mir-34a mimics, an inhibitor and over-expressing lentivirus were used in vitro and in vivo, respectively. Real-time PCR, immunohistochemistry, ELISA, cell proliferation assays, osteoblastic differentiation, and endothelial activity assays were employed to evaluate the effect of mir-34a on mMSCs, osteoblasts, and vascular endothelial cells in glucocorticoid-treated mice. We found that Dex inhibited mMSC proliferation and osteoblastic differentiation, as well as the viability and activity of endothelial cells. Dex also caused osteonecrosis and decreased new vessel formation in vivo. Mir-34a alleviated the inhibitory effects of Dex on mMSCs and osteoblasts, while facilitating its inhibitory effects on endothelial cells. Mir-34a is an important regulator in osteogenesis and angiogenesis, and it might be useful as a therapeutic target for GIOFH. ? 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:417?424, 2018.
ER  - 

TY  - JOUR
TI  - Abstracts—Symposia
JO  - Alcoholism: Clinical and Experimental Research
VL  - 34
IS  - s2
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2010.01211.x
DO  - doi:10.1111/j.1530-0277.2010.01211.x
SP  - 245A
EP  - 301A
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 125
IS  - S2
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.13297
DO  - doi:10.1111/bcpt.13297
SP  - 3
EP  - 330
PY  - 2019
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 289–2348)
JO  - Hepatology
JA  - Hepatology
VL  - 70
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.30941
DO  - doi:10.1002/hep.30941
SP  - 188
EP  - 1382
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts—Speakers
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 41
IS  - S1
SN  - 0145-6008
UR  - https://doi.org/10.1111/acer.13392
DO  - doi:10.1111/acer.13392
SP  - 265A
EP  - 338A
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Panel [Pancreas]
JO  - HPB
JA  - HPB
VL  - 16
IS  - s2
SN  - 1365-182X
UR  - https://doi.org/10.1111/hpb.12236
DO  - doi:10.1111/hpb.12236
SP  - 603
EP  - 697
PY  - 2014
ER  - 

TY  - JOUR
AU  - Loera-Valencia, R.
AU  - Cedazo-Minguez, A.
AU  - Kenigsberg, P.A.
AU  - Page, G.
AU  - Duarte, A.I.
AU  - Giusti, P.
AU  - Zusso, M.
AU  - Robert, P.
AU  - Frisoni, G. B.
AU  - Cattaneo, A.
AU  - Zille, M.
AU  - Boltze, J.
AU  - Cartier, N.
AU  - Buee, L.
AU  - Johansson, G.
AU  - Winblad, B.
TI  - Current and emerging avenues for Alzheimer's disease drug targets
JO  - Journal of Internal Medicine
JA  - J Intern Med
VL  - 286
IS  - 4
SN  - 0954-6820
UR  - https://doi.org/10.1111/joim.12959
DO  - doi:10.1111/joim.12959
SP  - 398
EP  - 437
KW  - AD gene therapy
KW  - AD molecular targets
KW  - AD therapeutics
KW  - alzheimer´s disease
KW  - amyloid beta therapies
KW  - Tau therapies
PY  - 2019
AB  - Abstract Alzheimer's disease (AD), the most frequent cause of dementia, is escalating as a global epidemic, and so far, there is neither cure nor treatment to alter its progression. The most important feature of the disease is neuronal death and loss of cognitive functions, caused probably from several pathological processes in the brain. The main neuropathological features of AD are widely described as amyloid beta (A?) plaques and neurofibrillary tangles of the aggregated protein tau, which contribute to the disease. Nevertheless, AD brains suffer from a variety of alterations in function, such as energy metabolism, inflammation and synaptic activity. The latest decades have seen an explosion of genes and molecules that can be employed as targets aiming to improve brain physiology, which can result in preventive strategies for AD. Moreover, therapeutics using these targets can help AD brains to sustain function during the development of AD pathology. Here, we review broadly recent information for potential targets that can modify AD through diverse pharmacological and nonpharmacological approaches including gene therapy. We propose that AD could be tackled not only using combination therapies including A? and tau, but also considering insulin and cholesterol metabolism, vascular function, synaptic plasticity, epigenetics, neurovascular junction and blood?brain barrier targets that have been studied recently. We also make a case for the role of gut microbiota in AD. Our hope is to promote the continuing research of diverse targets affecting AD and promote diverse targeting as a near-future strategy.
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - American Journal of Transplantation
VL  - 10
IS  - s4
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6143.2010.03108.x
DO  - doi:10.1111/j.1600-6143.2010.03108.x
SP  - 213
EP  - 571
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 112
IS  - S2
SN  - 0042-9007
UR  - https://doi.org/10.1111/vox.12601
DO  - doi:10.1111/vox.12601
SP  - 5
EP  - 191
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 60
IS  - s4
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2012.04000.x
DO  - doi:10.1111/j.1532-5415.2012.04000.x
SP  - S1
EP  - S242
PY  - 2012
ER  - 

TY  - JOUR
TI  - Paper Abstract
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 65
IS  - S1
SN  - 0002-8614
UR  - https://doi.org/10.1111/jgs.14915
DO  - doi:10.1111/jgs.14915
SP  - S1
EP  - S289
PY  - 2017
ER  - 

TY  - JOUR
TI  - SARS Abstracts
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 103
IS  - S3
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.10158
DO  - doi:10.1002/bjs.10158
SP  - 6
EP  - 49
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 165
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1111/bjh.12802
DO  - doi:10.1111/bjh.12802
SP  - 1
EP  - 103
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 111
IS  - S1
SN  - 1464-4096
UR  - https://doi.org/10.1111/bju.12069
DO  - doi:10.1111/bju.12069
SP  - 13
EP  - 119
PY  - 2013
ER  - 

AU  - Kalogeris, Theodore
AU  - Baines, Christopher P.
AU  - Krenz, Maike
AU  - Korthuis, Ronald J.
C7  - pp. 113-170
TI  - Ischemia/Reperfusion
UR  - https://doi.org/10.1002/cphy.c160006
DO  - doi:10.1002/cphy.c160006
SP  - 113-170
PY  - 2013
AB  - ABSTRACT Ischemic disorders, such as myocardial infarction, stroke, and peripheral vascular disease, are the most common causes of debilitating disease and death in westernized cultures. The extent of tissue injury relates directly to the extent of blood flow reduction and to the length of the ischemic period, which influence the levels to which cellular ATP and intracellular pH are reduced. By impairing ATPase-dependent ion transport, ischemia causes intracellular and mitochondrial calcium levels to increase (calcium overload). Cell volume regulatory mechanisms are also disrupted by the lack of ATP, which can induce lysis of organelle and plasma membranes. Reperfusion, although required to salvage oxygen-starved tissues, produces paradoxical tissue responses that fuel the production of reactive oxygen species (oxygen paradox), sequestration of proinflammatory immunocytes in ischemic tissues, endoplasmic reticulum stress, and development of postischemic capillary no-reflow, which amplify tissue injury. These pathologic events culminate in opening of mitochondrial permeability transition pores as a common end-effector of ischemia/reperfusion (I/R)-induced cell lysis and death. Emerging concepts include the influence of the intestinal microbiome, fetal programming, epigenetic changes, and microparticles in the pathogenesis of I/R. The overall goal of this review is to describe these and other mechanisms that contribute to I/R injury. Because so many different deleterious events participate in I/R, it is clear that therapeutic approaches will be effective only when multiple pathologic processes are targeted. In addition, the translational significance of I/R research will be enhanced by much wider use of animal models that incorporate the complicating effects of risk factors for cardiovascular disease. ? 2017 American Physiological Society. Compr Physiol 7:113-170, 2017.
ER  - 

TY  - JOUR
TI  - ePoster Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 21
IS  - s1
UR  - https://doi.org/10.1111/ene.12496
DO  - doi:10.1111/ene.12496
SP  - 104
EP  - 387
PY  - 2014
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 58
IS  - S1
UR  - https://doi.org/10.1002/hep.26727
DO  - doi:10.1002/hep.26727
SP  - 208A
EP  - 1309A
PY  - 2013
ER  - 

TY  - JOUR
TI  - Tissue Engineering and Regenerative Medicine
JO  - Journal of Tissue Engineering and Regenerative Medicine
VL  - 6
IS  - s1
UR  - https://doi.org/10.1002/term.1586
DO  - doi:10.1002/term.1586
SP  - 1
EP  - 429
PY  - 2012
ER  - 
